

**REMARKS/ARGUMENTS**

This Amendment supplements the Amendment of October 24, 2008 filed with the Request for Continued Examination.

The claims are further amended to delete claim 25 and change the dependencies of claims 28 and 29 to independent claim 15.

Supplementing the comments and remarks concerning claim 27 (page 8, center of the October 24, 2008 Amendment) applicants draw the examiner's attention not only to the Priel et al J. Virology 1991, 4137, but also Li et al, PNAS 1993, 1839 and, in addition, the attached article by Horwitz et al, Antiviral Action of Camptothecin from the Antimicrobial Agents and Chemotherapy Journal, Nov. 1972, pages 395-401.


With respect to the provisional obviousness-type double patenting rejections, applicants dispute the examiner's position and feel that the three referenced application are not reasonably related to the claims of the present application in terms of the compounds involved. More specifically, patent application 11/596,016 refers to t-butoxyiminocamptothecin derivatives conjugated in position 20 with integrin antagonists; patent application 11/596,015 refers to camptothecins conjugated in position 7 with integrin antagonists; patent application 11/596,189 refers to camptothecin derivatives conjugated in position 20 with integrin antagonists.

The examiner is requested to take the above amendments and comments into account during further examination of this application.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: \_\_\_\_\_

  
Arthur R. Crawford  
Reg. No. 25,327

ARC:eaw  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100